16 October 2020 : Clinical Research
Single Large Nodule (>5 cm) Prognosis in Hepatocellular Carcinoma: Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B?
Li Wan12BCDE, Ding-Hui Dong1ABCDE, Xiao-Ning Wu1BCD, Hong-Fan Ding1BCD, Qiang Lu1BCD, Yong Tian2BC, Xu-Feng Zhang1ABCDEFG*, Wenzhi Li13ADEDOI: 10.12659/MSM.926797
Med Sci Monit 2020; 26:e926797
Table 1 Characteristics of the patients with hepatocellular carcinoma in BCLC stages A1, A2, and B.
| Variables | BCLC stages A1 (n=455) | BCLC stage A2 (n=188) | BCLC stage B (n=362) |
|---|---|---|---|
| Male sex | 366 (80.4%) | 154 (81.9%) | 292 (80.7%) |
| Age (years) | 55 (24–82) | 54 (22–82) | 55 (13–87) |
| History of cigarette smoking | 188 (41.3%) | 87 (46.3%) | 151 (41.7%) |
| History of alcohol abuse | 145 (31.9%) | 65 (34.6%) | 113 (31.2%) |
| Diabetes# | 42 (9.2%) | 22 (11.7%) | 18 (5.0%) |
| HBV positivity | 338 (74.2%) | 133 (70.7%) | 249 (68.8%) |
| HCV positivity | 34 (7.5%) | 7 (3.7%) | 16 (4.4%) |
| Liver cirrhosis | 314 (69.0%) | 121 (64.4%) | 229 (63.3%) |
| Child-Pugh class B# | 31 (6.8%) | 19 (10.1%) | 15 (4.1%) |
| AFP >200 ng/ml | 222 (48.8%) | 109 (58.0%) | 186 (51.4%) |
| Primary treatments | |||
| Surgical resection | 155 (34.1%) | 49 (26.1%) | 130 (35.9%) |
| Radiofrequency ablation* | 129 (28.4%) | 32 (17.0%) | 43 (11.9%) |
| TACE* | 148 (32.5%) | 86 (45.7%) | 159 (43.9%) |
| Supportive treatments* | 23 (5.1%) | 21 (11.1%) | 30 (8.3%) |
| 30-day mortality | 17 (3.7%) | 8 (4.3%) | 10 (2.8%) |
| 90-day mortality | 28 (6.2%) | 14 (7.4%) | 30 (8.3%) |
| HCC – hepatocellular carcinoma; BCLC – Barcelona Clinic Liver Cancer; HBV – hepatitis B virus; HCV – hepatitis C virus; AFP – alpha-fetoprotein; TACE – transarterial chemoembolization. * # | |||